Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNC0487-0111 in people who have excess body weight and knee osteoarthritis. This study compares two doses of NNC0487-0111 given as weekly injections under the skin against a placebo, with the goal of helping participants lose weight and reduce knee pain. Participants have knee osteoarthritis confirmed by clinical and radiographic criteria and will follow a reduced-calorie diet and increased physical activity throughout the study. Participants will be randomly assigned to receive one of three treatments NNC0487-0111 dose level 1, NNC0487-0111 dose level 2, or a placebo, all given once weekly by subcutaneous injection using a pre-filled pen injector. The injections will be administered to the thigh, abdomen, or upper arm. All participants will be encouraged to follow a reduced-calorie diet and increase physical activity during the trial. The treatment period lasts for 80 weeks. Throughout the study, participants will have regular assessments of body weight, knee pain, physical function, and other health measures. Researchers will collect data on changes in weight, knee pain scores using the WOMAC index, physical function, blood pressure, cholesterol levels, blood sugar markers, and use of pain medication. Safety will be monitored through reporting of adverse events. The study is expected to continue until August 2028, with visits and evaluations occurring at scheduled intervals during the treatment period.
Actively Recruiting
Researchers are evaluating how well people with small cell lung cancer SCLC tolerate different doses of alisertib when combined with paclitaxel. This Phase 2 open-label trial focuses on patients who have had prior treatments including platinum-based chemotherapy and immunotherapy. The study aims to understand the side effects participants experience based on standardized criteria during treatment cycles. Participants take alisertib orally twice a day from Day 1 through Day 7 in each 21-day cycle, with doses starting at 30 mg twice daily and increasing by 10 mg in successive groups of about ten participants. Paclitaxel is given intravenously on Days 1 and 8 of each cycle. After each cycle involving alisertib, participants receive a preventive injection called granulocyte-colony stimulating factor G-CSF to support the bodys defenses. Blood samples are collected on Days 1 and 7 of the first two cycles to monitor alisertib levels. Treatment continues until disease progression, unacceptable side effects, death, or withdrawal from the study. After stopping treatment, participants enter a long-term follow-up phase with contact every 8 weeks until death, study end, or withdrawal. Researchers assess side effects, response to treatment, disease control, progression-free survival, and overall survival over up to 24 months, carefully monitoring safety throughout the study.
Actively Recruiting
Researchers are evaluating a new medicine called Sofetabart Mipitecan Sofe-M in a three-part clinical trial for people with certain types of ovarian, peritoneal, and fallopian tube cancers. The study focuses on patients with platinum-resistant cancer, whose disease worsened during or within six months after platinum chemotherapy, and those with platinum-sensitive cancer, whose disease remained controlled for at least six months after platinum treatment. The trial aims to determine if Sofe-M is more effective and to better understand its safety compared to standard treatments. Participants receive different treatments depending on their group. In Part A, patients with platinum-resistant disease receive Sofetabart Mipitecan or chemotherapy or Mirvetuximab Soravtansine, all given intravenously. In Parts B and C, patients with platinum-sensitive disease receive Sofetabart Mipitecan plus Bevacizumab or platinum-based chemotherapy plus Bevacizumab, also administered intravenously. The choice of chemotherapy is made by the investigator. Treatments are given in parallel groups. During the study, participants undergo regular assessments including imaging scans to monitor disease progression, safety evaluations, and quality of life questionnaires. Researchers measure progression-free survival as the primary outcome, along with overall survival, response rates, symptom changes, and drug levels in the blood. Each participants time in the study varies based on their response to treatment, with follow-up continuing up to 70 months after randomization to track outcomes and safety.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNC0487-0111 in adults with excess body weight and knee osteoarthritis. This phase 3 study compares NNC0487-0111 to a placebo to determine its impact on weight loss and knee pain reduction. Participants have symptomatic knee osteoarthritis confirmed by clinical and radiographic criteria and experience knee pain for more than 90 days. Participants receive subcutaneous injections of either NNC0487-0111 or placebo once weekly. Both groups follow a reduced-calorie diet and increased physical activity as part of the treatment plan. The study uses pre-filled pen-injectors for administration at one of three body sites thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks. During the study, participants will be monitored through various assessments including body weight, knee pain using the WOMAC pain score, physical function, blood pressure, cholesterol levels, blood glucose, and use of pain medications. Safety will be tracked by recording adverse events up to 84 weeks. Participants will complete questionnaires and have clinical evaluations at regular intervals throughout the trial.
Actively Recruiting
Researchers are evaluating tanruprubart, also known as ANX005, in people aged 8 to 85 years with Guillain-Barre Syndrome GBS. This phase 3 open-label study aims to understand how tanruprubart behaves in the body, its effects on the immune system, early signs of its impact on GBS, and its safety profile across adult and pediatric participants in the United States, Canada, and Europe. Participants will receive a single intravenous infusion of tanruprubart at a dose of 30 mg per kilogram on the first day of the study. This single-dose treatment is designed to assess the pharmacokinetics and pharmacodynamics of the drug, along with early efficacy signals and safety data during the initial 15 days following infusion. During the study, participants will be monitored through blood tests measuring tanruprubart concentration and complement protein levels, as well as clinical assessments such as the Medical Research Council Sumscore to evaluate muscle strength changes. Researchers will focus on drug concentration over time and the time to reach maximum serum concentration. The primary measurement period extends up to day 15, with safety and efficacy monitored closely throughout this timeframe.
Actively Recruiting
Researchers are evaluating whether adding Quizartinib to the combination of Venetoclax and Azacytidine improves overall survival compared to Venetoclax and Azacytidine alone in adults with newly diagnosed acute myeloid leukemia AML who are not suitable for standard induction chemotherapy due to age, other health conditions, or risk factors. This Phase III trial will randomize participants to compare the two treatment regimens. Participants will be assigned to one of two groups the experimental group will receive Azacytidine as a subcutaneous injection daily on days 1 to 7 of each 28-day cycle, Venetoclax orally daily on days 1 to 7, and Quizartinib orally on days 8 to 21 with dose adjusted by FLT3-ITD mutation status. The standard group will receive Azacytidine daily on days 1 to 7 and Venetoclax daily for 28 days in each 28-day cycle. Treatment continues until disease progression, unacceptable side effects, withdrawal, or other protocol-defined reasons. During the study, participants will have regular clinical visits and follow-up assessments, with survival data collected every three months for two years after the last participant finishes treatment. Researchers will monitor overall survival over four years as the primary outcome, along with event-free survival and complete response rates. Safety and treatment effects will be tracked throughout the study period.
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are evaluating the efficacy, safety, and tolerability of zeleciment basivarsen DYNE-101 for treating myotonic dystrophy type 1 DM1. This phase 3 study includes participants diagnosed with DM1 confirmed by genetic testing and aims to assess the impact of DYNE-101 on physical function and disease symptoms. Participants are randomly assigned to receive either DYNE-101 or a matching placebo through intravenous infusion every 8 weeks during a 48-week placebo-controlled period. Following this, all participants enter a 24-week long-term extension where those initially on placebo switch to DYNE-101, and those on DYNE-101 continue the treatment. An Independent Data Monitoring Committee oversees safety and tolerability throughout the study. Participants undergo evaluations including the 5 Times Sit-To-Stand test as the primary outcome and various secondary measures such as hand opening time, muscle strength tests, walking speed, and patient and clinician global impressions. Blood samples are collected to monitor drug levels and immune responses. The total participation time may last up to approximately 80 weeks, including screening, treatment, and long-term follow-up assessments.
Actively Recruiting
Researchers are studying how regular physical exercise affects women with early-stage breast cancer who are undergoing adjuvant hormone therapy. This study involves 150 women who have completed their primary cancer treatments and are in the first three months of hormone therapy. The goal is to see how exercise improves quality of life, physical fitness, nutrition, and biological factors like the immune system and gut bacteria. Participants take part in a 16-week supervised exercise program with two sessions per week, one in a gym and one in a pool. The program progresses through four monthly stages adaptation, base building, moderate progression, and consolidation, with exercise intensity tailored using heart rate monitors and exertion scales. Throughout the study, participants use a mobile app and wearable devices to track activity, sleep, and symptoms. Participants attend five hospital visits for assessments including body scans to measure bone and muscle health, blood and biological sample collections to study genetics, immune markers, and gut microbiota, and questionnaires about quality of life, mood, sleep, and cognition. Researchers monitor changes during the study and for about a year afterward to evaluate how exercise affects health and well-being, supported by digital health tools and machine learning to personalize care.
1-10 of 16
1